Welcome to our dedicated page for Tvardi Therapeutics news (Ticker: TVRD), a resource for investors and traders seeking the latest updates and insights on Tvardi Therapeutics stock.
Tvardi Therapeutics, Inc. (NASDAQ: TVRD) is a clinical-stage biopharmaceutical company whose news flow centers on the development of oral small molecule therapies targeting STAT3 for fibrosis-driven diseases and oncology indications. Company press releases consistently describe Tvardi as focused on STAT3, a transcription factor it identifies as a central mediator of fibrotic signaling pathways and as involved in cancer cell survival and immune evasion.
News updates for TVRD commonly cover progress in clinical trials of its lead STAT3 inhibitor TTI-101 and its next-generation STAT3 inhibitor TTI-109. Tvardi has issued detailed announcements on the REVERT IPF Phase 2 clinical trial of TTI-101 in idiopathic pulmonary fibrosis, including completion of enrollment, preliminary data indicating that the study did not meet its goals, and subsequent analyses examining fibrosis scores, inflammatory markers such as IL-6, and pulmonary function measures like Forced Vital Capacity. Additional news highlights the REVERT Liver Cancer Phase 1b/2 trial of TTI-101 in hepatocellular carcinoma and the initiation and progress of a healthy volunteer study of TTI-109.
Investors and followers of TVRD news can also expect regular financial and business updates, including quarterly results, cash runway disclosures, and commentary on upcoming clinical milestones. Tvardi frequently announces participation in healthcare and biotechnology investor conferences, such as events hosted by J.P. Morgan, Piper Sandler, Jefferies, Cantor and BTIG, where management provides corporate presentations and engages with investors.
This news page aggregates Tvardi’s press releases and related coverage so readers can track clinical trial developments, data readouts, regulatory milestones, and corporate communications related to its STAT3-targeted programs. For those monitoring TVRD stock, the news stream offers insight into how Tvardi’s clinical and corporate activities evolve over time.
Tvardi Therapeutics (NASDAQ: TVRD) will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026. Tvardi is a clinical-stage biopharmaceutical focused on oral small-molecule therapies targeting STAT3 for inflammatory and proliferative diseases.
Tvardi Therapeutics (NASDAQ: TVRD) reported fourth-quarter and full-year 2025 results and provided a clinical update. Cash, cash equivalents and short-term investments were $30.8M as of Dec 31, 2025, with a runway expected into Q4 2026. Net loss for 2025 was $18.2M versus $29.4M in 2024.
Clinical milestones: topline healthy volunteer data for next-generation STAT3 inhibitor TTI-109 expected in Q2 2026; topline Phase 1b/2 REVERT LIVER CANCER results for TTI-101 anticipated in H2 2026. REVERT IPF analysis showed a 9.4% fibrosis reduction vs 2.4% for placebo.
Tvardi Therapeutics (NASDAQ: TVRD) announced management will participate in four investor events in February–March 2026: JonesTrading C-Suite (Feb 19), Oppenheimer Healthcare Life Sciences (Feb 25), TD Cowen Health Care (Mar 3) and Barclays Global Healthcare (Mar 10).
Webcasts for JonesTrading and Oppenheimer will stream on the Tvardi investors website, with replays available for about 90 days.
Tvardi Therapeutics (NASDAQ: TVRD) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 PM PT. Management will discuss new Phase 2 REVERT IPF clinical trial data for TTI-101 released the same day, which the company described as showing encouraging signals across fibrosis markers, inflammatory markers, and pulmonary function tied to STAT3 inhibition. The presentation will be held in California East at The Westin St. Francis and will be webcast on the Tvardi investor website; a replay will be available for ~90 days.
Tvardi Therapeutics (NASDAQ: TVRD) reported additional analyses from its Phase 2 REVERT IPF trial of TTI-101, focusing on 40 patients exposed to study drug for 12 weeks (16 pooled TTI-101, 24 placebo). Key findings: fibrosis score declined -9.4% with TTI-101 vs -2.4% for placebo (centrally read); greater IL-6 reductions observed with TTI-101, especially in patients with higher baseline IL-6; 63% of TTI-101 patients had FVC increases at 12 weeks vs 46% placebo, and mean FVC change was -15mL vs -22mL for REVERT placebo. The company noted the Phase 2 study overall did not meet its goals and is awaiting Phase 1 TTI-109 healthy volunteer topline data in H1 2026.
Tvardi Therapeutics (NASDAQ: TVRD) announced that management will participate in the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025. Tvardi will host a fireside chat on Tuesday, December 2, 2025 at 12:00 PM ET and hold one-on-one investor meetings. The company said the fireside chat will be webcast on the Tvardi investor website, with a replay available for approximately 90 days following the conference.
Tvardi Therapeutics (NASDAQ: TVRD) reported third quarter 2025 results and a business update highlighting clinical and cash milestones. The company expects topline Phase 2 TTI-101 HCC data in H1 2026 and healthy volunteer results for next-generation TTI-109 in H1 2026 after its IND went into effect. In October, Tvardi reported that the Phase 2 REVERT IPF trial did not meet its goals and is conducting additional analyses. Financially, Q3 R&D was $3.6M versus $4.8M year-ago, G&A rose to $2.3M from $0.9M, net loss was $5.5M, and cash plus short-term investments were $36.5M, with a runway into Q4 2026.
Tvardi Therapeutics (NASDAQ: TVRD) said company management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 AM GMT and will hold investor one-on-one meetings during the event. The conference runs November 17–20, 2025 in London, UK. The presentation will be webcast on the Tvardi investor website and a replay will be available for approximately 90 days following the conference.
This is a presentation by a clinical-stage biopharma focused on oral small-molecule STAT3 inhibitors for fibrosis-driven diseases; the company will discuss its near- and longer-term development and investor outreach at the conference.
Tvardi Therapeutics (NASDAQ: TVRD) reported preliminary Phase 2 REVERT results in idiopathic pulmonary fibrosis showing the study did not meet its goals. 88 patients were randomized to TTI-101 400mg (n=30), 800mg (n=29) or placebo (n=29); 58% received concomitant nintedanib.
Baseline percent predicted FVC was lower in placebo (70.1%) versus TTI-101 arms (74.1%, 81.1%). Discontinuation rates were 10.3% placebo vs 56.7% (400mg) and 62.1% (800mg), driven mainly by gastrointestinal adverse events, higher with nintedanib. At 12 weeks mean FVC change (mL) was placebo -22.2 (n=24), 400mg -61.1 (n=8), 800mg -102.8 (n=13).
Company has $41.0M cash, funding operations into Q4 2026, and expects preliminary topline TTI-109 healthy-volunteer data and TTI-101 HCC Phase 2 data in H1 2026.
Tvardi Therapeutics (NASDAQ: TVRD), a clinical-stage biopharmaceutical company developing oral STAT3-targeting therapies for fibrosis-driven diseases, will participate in the Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on September 4, 2025 at 2:10 PM EDT and conduct one-on-one investor meetings.
The fireside chat will be available via webcast on Tvardi's Investors' website, with replay access for approximately 90 days after the conference.